Abstract: Provided are methods for assigning a subject having idiopathic multicentric Castleman disease (iMCD) to a group having a higher or lower probability of responding to treatment for iMCD using measured quantities of CXCL13. Also disclosed are methods of treating idiopathic multicentric Castleman disease (iMCD) in a subject in need thereof comprising administering to the subject an inhibitor of CXCL13 or of CXCR5. Also provided herein are methods for assigning a subject having idiopathic multicentric Castleman disease (iMCD) to a group having a higher or lower probability of responding to treatment for iMCD using measured quantities of specified biomarkers. The present disclosure also provides methods of treating idiopathic multicentric Castleman disease (iMCD) in a subject in need thereof comprising administering to the subject an inhibitor of the JAK-STAT3 pathway. Also disclosed are methods for assessing the absence or presence of iMCD in a subject.

Abstract: The present disclosure provides methods and compositions for enhancing utrophin protein production by inhibiting binding of a Let-7c microRNA molecule to its binding site in the utrophin mRNA 3?-untranslated region (UTR). In particular, phosphorodiamidate morpholino oligonucleotide (PMO) site blocking oligonucleotides (SBOs) that inhibit Let-7c miRNA binding to its binding site in the utrophin mRNA 3?UTR. Moreover. methods of enhancing utrophin protein production in muscle cells can be used to treat muscular dystrophy and/or other myopathies.

Abstract: A method for designing a knitted textile or fabric, the method includes receiving graphical input from a user regarding a knit pattern comprised of different types of individual stitches to be included in a textile or fabric design. The method further includes graphically displaying a representation of the textile or fabric design. The method further includes merging sections of continuous stitches of the same type into at least one block. The method further includes graphically displaying the textile or fabric design as a pattern of the at least one block. The method further includes applying edge rolling indicators and/or folding indicators to the displayed pattern of the at least one block, where the edge rolling and/or folding indicators respectively and graphically illustrate predicted edge rolling and folding behaviors of a physical textile or fabric.

Abstract: Methods of making robust bijels include dispersing metal oxide precursors and/or metal salts into at least one phase of a bijel and hydrolyzing and condensing the metal oxide precursors and/or metal salts in a sol-gel reaction to form sintered bridges between interfacially jammed surface-active nanoparticles. The methods can be used with any bijels, including those produced during solvent transfer-induced phase separation (STRIPS) methods and other methods. A robust bijel includes chemically sintered bridges between the interfacially jammed surface-active nanoparticles. Methods of making nanocatalyst-functionalized sintered bijels include adsorbing metal salts to a surface of sintered interfacially jammed nanoparticles of bijels, and reducing the metal precursors on the surface of the sintered nanoparticles. Nanocatalyst-functionalized sintered bijels include catalytically active metal or metal oxide nanocatalysts on a surface of the sintered interfacially jammed surface-active nanoparticles.

Abstract: Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis and/or cirrhosis in OTCD patients by administering hOTC.

Abstract: A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.

Abstract: Methods and systems for analyzing images are disclosed. An example method may comprise inputting one or more of a first image or a second image into a fully convolutional network, and determining an updated fully convolutional network by optimizing a similarity metric associated with spatially transforming the first image to match the second image. The one or more values of the fully convolutional network may be adjusted to optimize the similarity metric. The method may comprise registering one or more of the first image or the second image based on the updated fully convolutional network.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemagglutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said composition and method of generation.

Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.

Abstract: Compositions and methods for treating type II diabetes in a feline are provided. A viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding a feline GLP-1 receptor agonist.

Abstract: Novel AAV capsids and recombinant AAV vectors comprising the same are provided.

Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.

Abstract: Provided are aptamer-functionalized graphene sensors, capable of detecting various analytes, including toxins, at comparatively low concentrations. Also provided are methods of fabricating and using such aptamer-functionalized graphene sensors.

Abstract: The invention relates to methods for providing prognosis, diagnosis, and treatment of a mild traumatic brain injury (mTBI) in a computed tomography (CT)-negative subject. The invention further relates to monitoring the severity of brain damage resulting from TBI in a subject and determining the prognosis of a subject that has suffered from mTBI. This invention also relates to methods of predicting who is at risk for developing brain damage and long-term dysfunction.

Abstract: An ambulatory respiratory assist device utilizes a cuirass worn on the chest and/or abdomen and supported by a hip belt so that it does not place a load on the patient's shoulders. The belt also supports a ventilator that includes a pump and its power supply, valving, controls and auxiliary equipment. The device is optionally integrated with auxiliary features such as chest wall vibration, which can be achieved by utilizing cuirass pressure modulation, with shoulder or upper arm supports for simulating the “tripod position”, with positive pressure ventilation apparatus, or with patient monitoring. Shoulder or upper arm supports can extend directly from the belt to the shoulders or upper arms, utilized independently of the cuirass, and optionally integrated with one or more of the above-mentioned auxiliary features.

Abstract: Provided herein are engineered nucleic acid sequences encoding AAVhu68 which provide improved yields of packaged AAVhu68 viral particles. Also provided is a packaging host cell comprising the engineered nucleotide sequence and methods of using same to product recombinant AAVhu68 vectors useful for gene delivery. Further provided are production cell supernatants comprising improved yields of recombinant AAV vectors having AAVhu68 capsids produced using the nucleotide sequences provided herein.

Abstract: A recombinant adeno-associated virus (rAAV) vector comprising an AAVhu68 capsid produced in a production system comprising a nucleotide sequence of SEQ ID NO: 1, or a sequence at least 75% identical thereto which encodes SEQ ID NO:2. The AAVhu68 capsid comprises subpopulations of highly deamidated asparagine residues in asparagine-glycine pairs in the amino acid sequence of SEQ ID NO: 2. Also provided are compositions containing the rAAV and uses thereof. Additionally, rAAV having an engineered AAV capsid comprising at least one subpopulation of vp1 or vp2 proteins having a Val at amino acid position 157 with reference to the AAVhu68 vp1 numbering are provided.

Abstract: The present invention includes compositions and methods for an HLA-A2 specific chimeric antigen receptor (CAR). In certain embodiments the HLA-A2 specific CAR is expressed on a T regulatory cell. In certain embodiments, the HLA-A2 specific CAR protects transplanted tissue from rejection.

Abstract: Compositions and methods are provided for treating ocular disorders in a subject are provided. In one aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGA3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGB3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding REP-1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.

Abstract: Compositions and methods for treating metabolic diseases in a subject are provided. A viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding a GLP-1 receptor agonist fusion protein and regulatory sequences which direct expression thereof.